A comparative analysis of dengue, chikungunya, and Zika manifestations in a
pediatric cohort over 18 years

Fausto Andres Bustos Carrillo, PhD;[1,2] Sergio Ojeda, MD;[3] Nery Sanchez, MD;[3] Miguel Plazaola,
MD;[3] Damaris Collado, BS;[3] Tatiana Miranda, BS;[3] Saira Saborio, MSc;[3] Brenda Lopez Mercado,
BS;[3] Jairo Carey Monterrey, BS;[3] Sonia Arguello, BS;[3] Lora Campredon, MPH;[4] Zijin Chu, MPH;[4]
Colin J. Carlson, PhD;[5] Aubree Gordon, PhD;[4] Angel Balmaseda, MD;[3,6] Guillermina Kuan, MD;[3,7]
Eva Harris, PhD[1]

[1] Division of Infectious Diseases and Vaccinology, School of Public Health, University of
California, Berkeley, Berkeley, California, USA
[2] Division of Epidemiology and Biostatistics, School of Public Health, University of California,
Berkeley, Berkeley, California, USA
[3] Sustainable Sciences Institute, Managua, Nicaragua
[4] Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor,
Michigan, USA
[5] Department of Epidemiology of Microbial Diseases, Yale University School of Public Health,
New Haven, CT, USA
[6] National Virology Laboratory, Centro Nacional de Diagnóstico y Referencia, Ministry of Health,
Managua, Nicaragua
[7] Centro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua

Aubree Gordon and Eva Harris hold the academic rank of Full Professor.

Key words: dengue; chikungunya; Zika; pediatric; cohort, afebrile dengue; arboviral diseases

Corresponding author: Eva Harris, Division of Infectious Diseases and Vaccinology, School of
Public Health, University of California, Berkeley, 185 Li Ka Shing Center, 1951 Oxford Street,
Berkeley, CA 94720-3370; Tel. 1-510-642-4845; eharris@berkeley.edu

ABSTRACT

Background. Dengue, chikungunya, and Zika are diseases of major human concern. Differential diagnosis is complicated in children and adolescents by their overlapping clinical features (signs, symptoms, and complete blood count results). Few studies have directly compared the three diseases. We aimed to identify distinguishing pediatric characteristics of each disease.

Methods. Data were derived from laboratory-confirmed cases aged 2-17 years enrolled in a longitudinal cohort study in Managua, Nicaragua, and attending a primary health care center from January 2006 through December 2023. We collected clinical records and laboratory results across the first 10 days of illness. Data were analyzed with generalized additive models, generalized linear mixed models, and machine learning models.

Findings. We characterized 1,405 dengue, 517 chikungunya, and 522 Zika pediatric cases. The prevalence of many clinical features exhibited by dengue, chikungunya, and Zika cases differed substantially overall, by age, and by day of illness. Dengue cases were differentiated most by abdominal pain, leukopenia, nausea, vomiting, and basophilia; chikungunya cases were differentiated most by arthralgia and the absence of leukopenia and papular rash; and Zika cases were differentiated most by rash and the lack of fever and lymphocytopenia. Dengue and chikungunya cases exhibited similar temperature dynamics during acute illness, and their temperatures were higher than Zika cases. Sixty-two laboratory-confirmed afebrile dengue cases, which would not be captured by any widely used international case definition, presented very similarly to afebrile Zika cases, though some exhibited warning signs of disease severity. The presence of arthralgia, the presence of basophilia, and the absence of fever were the most important model-based distinguishing predictors of chikungunya, dengue, and Zika, respectively.

Interpretations. These findings substantially update our understanding of dengue, chikungunya, and Zika in children while identifying various clinical features that could improve differential diagnoses. The occurrence of afebrile dengue warrants reconsideration of current case definitions.

Funding. US National Institutes of Health R01AI099631, P01AI106695, U01AI153416, U19AI118610.

Research in context

Evidence before this study: Dengue, chikungunya, and Zika co-occur in tropical and subtropical
settings and cause fever, rash, and other clinical features. We reviewed widely used international
case definitions for the three diseases; the Pan American Health Organization's (PAHO) 2022
report on differential diagnosis of the diseases; and the 80 studies underlying PAHO's diagnostic
recommendations. On March 15, 2025, we queried PubMed without restrictions for "pediatric
cohort" AND "dengue" AND "chikungunya" AND "Zika," revealing that no other pediatric cohort
simultaneously reported clinical differences between the three diseases. The literature suggests
that dengue, chikungunya, and Zika have a broad and overlapping set of clinical manifestations
that hamper differential diagnosis and case management absent definitive laboratory testing. Mild
forms of the diseases during acute illness typically produce the greatest overlap in presentation.
Most studies on the diseases' clinical manifestations are in adults, and these studies constitute
the main evidence base for existing case definitions. For example, only one of 80 studies
summarized in PAHO's recent report directly compared clinical features across cases
experiencing dengue, chikungunya, and Zika, and that study mainly focused on adults. Disease
presentation is more non-specific in children and adolescents than in adults, further impeding
differential diagnoses in pediatric populations. Current guidelines suggest that the presence of
thrombocytopenia, progressive increases in hematocrit, and leukopenia tend to distinguish
dengue from chikungunya and Zika; that arthralgia is more common in chikungunya; and that
pruritis is more common in Zika. All dengue case definitions in widespread use require that
patients exhibit fever.

Added value of this study: This study follows a cohort of Nicaraguan children through multiple
dengue epidemics, two large chikungunya epidemics, and one explosive Zika epidemic. By
synthesizing 18 years' worth of primary care medical records, we find clinically meaningful
differences in the prevalence of many clinical features, including by day of illness and across age,
but not by sex. In addition to verifying the clinical features PAHO identified as key distinguishing
features, we also identified others, including papular rash, nausea, hemorrhagic manifestations,
abdominal pain, and basophilia, that could aid differential diagnoses. As the PAHO report is based
on a multitude of studies with varied age ranges, health care accessibility, overall research quality,
and patient populations, this study is a complementary and important counterpart that draws from
a single, well-characterized source population. Further, we identified 62 laboratory-confirmed
cases of afebrile dengue (7·1% of all dengue cases since we started testing any suspected case
exhibiting afebrile rash). The disease manifestations of afebrile dengue cases were generally

clinically indistinguishable from afebrile Zika, although several displayed warning signs of severity.
We found that cases of the three diseases exhibited different temperature dynamics across the
acute period of illness. Machine learning models best distinguished chikungunya (an alphaviral
disease) from dengue and Zika (flaviviral diseases) based on clinical features. Our dengue model
performed well, especially in classifying febrile dengue cases. However, our Zika model struggled
to properly distinguish afebrile dengue cases from afebrile Zika cases, likely due to their very
similar and minimal disease presentation.
105
Implications of all the available evidence: Despite clinical overlap in the pediatric
manifestations of dengue, chikungunya, and Zika, we identify meaningful differences in their
presentation and in laboratory markers that can be leveraged to improve diagnoses in the
absence of definitive laboratory-based diagnostic testing. Afebrile dengue should be studied more
and incorporated into future case definitions, as not accounting for its existence can impede
surveillance, laboratory testing strategies, clinical management, and research efforts.

INTRODUCTION

Dengue virus (DENV), chikungunya virus (CHIKV), and Zika virus (ZIKV) are primarily transmitted by *Aedes aegypti* and *Aedes albopictus* mosquitoes. Over four billion people in the tropics and subtropics live at risk of infection (1), and climate change is exacerbating the risk for billions more (2). Where viruses overlap geographically, explosive co-epidemics with high morbidity sometimes occur, as seen across Central and South America, Africa, and Asia.

Four DENV serotypes (DENV-1-4) cause dengue, the world's most common mosquito-borne disease, which ranges from undifferentiated fever to life-threatening conditions (3–5). Fever and arthralgia are especially prominent during acute-phase chikungunya; some patients experience persistent arthralgia months or years afterward (6). Zika often presents non-specifically during childhood and as a mild, dengue-like disease in adolescence and adulthood (7). However, ZIKV infection during pregnancy can cause serious developmental complications in infants, including microcephaly.

The clinical spectrum of dengue, chikungunya, and Zika encompasses fever, rash, and other clinical features (*i.e.*, signs, symptoms, and complete blood count results) (5). As the most common and mild forms of these typically self-limiting diseases display overlapping clinical features, primary care physicians may face challenges in generating an accurate diagnosis, especially during contemporaneous outbreaks. An additional pediatric complication is that the diseases tend to present distinctly in adults but more non-specifically in children and adolescents. Differential diagnosis and disease surveillance may thus be especially difficult in pediatric populations absent definitive laboratory testing. Further, rapid tests, which are expensive or unavailable in many resource-limited areas, may be insufficient to distinguish dengue from Zika cases as DENV and ZIKV are similar flaviviruses with high structural and sequence homology that display antigenic cross-reactivity. In response, a recent Pan American Health Organization (PAHO) report identified clinical features useful for differential diagnosis by summarizing 80 studies with varied patient populations, age ranges, research quality, and health care settings (8). However, only one of 80 studies directly compared the prevalence of clinical features across the diseases, and that study (9) mainly focused on adults, leaving a wide gap in pediatric medicine.

We aimed to use 18 years of primary care observations from a Nicaraguan pediatric cohort to characterize the distinguishing features of dengue, chikungunya, and Zika. Specifically, we examined whether clinical features varied in prevalence overall, by age, by sex, and by day of

illness; assessed the temporal dynamics of fever for disease-specific differences; and leveraged

our study design to characterize cases of afebrile dengue. Finally, we developed machine learning

classification models to quantify how accurately differential diagnosis can be performed

algorithmically given the overlapping nature of the diseases and to identify the most important

clinical features for disease classification.

METHODS

Study design and participants

Briefly, in 2004, the PDCS began studying DENV infections among 2-9-year-old children in

Managua, Nicaragua (10). The PDCS expanded its eligibility criteria to include CHIKV and ZIKV

before they entered the study area in August 2014 and January 2016, respectively (11,12). After

several age-based expansions (2-11 in 2008, 2-14 in 2013), the study has included 2-17-year-

olds since 2018, after the chikungunya and Zika epidemics. PDCS participants receive free

medical care 24 hours per day, 7 days per week at the Health Center Sócrates Flores Vivas

(HCSFV). Participants are encouraged to visit the HCSFV at the first indication of any illness and

to return if new signs or symptoms occur; the vast majority (95·1%) of participants comply (10).

During each medical visit, information on over 100 clinical features is currently collected

(appendix, p 2). Acute blood samples are collected at the first medical consult (97·0% within 1-3

days of illness) and may be collected at subsequent visits, depending on physicians' judgement

and ethical constraints on the repeated collection of blood from young children. Convalescent

samples are collected 14-21 days post-illness onset (94·0% of cases). Medical data is collected

when cases present to the HCSFV. As the HCSFV is a primary health care setting, it generally

does not admit patients for the entire duration of their acute illness.

We assessed clinical features during the first 10 days of illness. Analysis was restricted to clinical

findings either 1) present in the World Health Organization (WHO) or PAHO case definitions for

dengue, chikungunya, or Zika (3–5,13–15) or 2) occurring in at least 30 cases of any of the three

diseases. Fever was defined as a recent history of fever or feverishness by the patient or guardian

or a measured temperature of $\geq$38·0°C (100·4°F) during the medical consult. *Rash*, unless

otherwise specified, denotes any type of rash.

We included laboratory-confirmed cases evaluated at the HCSFV between January 2006 and

December 2023. Patient and laboratory data undergo extensive validation to ensure accuracy

(10). For this study, we reassessed the data for consistency and completeness. Incomplete

clinical records were excluded. Medical personnel reviewed moderate-to-severe discrepancies in
patient data. Medically irreconcilable data were excluded.

We involved people with lived experience in Managua, Nicaragua, across all stages of the
research, including the funding application, study design, research implementation, and
manuscript preparation. Well over half the authors (n=11, 65%) live in Managua, including the
study physicians (n=4), who have decades of experience treating children with dengue,
chikungunya, and Zika. Study clinicians reviewed medical records, guided the selection of clinical
features to evaluate, ensured that variables were defined consistent with clinical standards set by
the Nicaraguan Ministry of Health, and provided feedback on drafts of this report. The broader
Nicaraguan study team includes more than 200 persons living in Managua whose professional
experiences and deep knowledge of the study setting continuously shape and improve the team's
research output. In all, the PDCS study team has authored over 150 research papers on the
clinical, epidemiological, and immunological properties of dengue, chikungunya, and Zika viruses,
all of which have featured Nicaraguan study members as authors.

Procedures
Initially, PDCS cases suspected of dengue, chikungunya, or Zika were eligible for laboratory
testing if they exhibited: 1) fever and ≥ 2 of the following: headache, retro-orbital pain, myalgia,
arthralgia, rash, hemorrhagic manifestations, and leukopenia (1997 WHO dengue case definition
(3)) or 2) undifferentiated fever without evident cause, with or without other clinical findings. After
ZIKV was introduced into Managua in 2016, PDCS testing criteria expanded to encompass a third
clinical profile: afebrile rash, with or without other clinical findings (7).

Suspected dengue and chikungunya cases were laboratory-confirmed by 1) RT-PCR of acute
blood samples, with some undergoing viral isolation, 2) seroconversion by IgM capture ELISA, or
3) seroconversion or a ≥ 4-fold increase (DENV only) in total anti-DENV antibody titers by
Inhibition ELISA in paired acute and convalescent samples. DENV serotyping was achieved by
RT-PCR. After the introduction of ZIKV, a flavivirus antigenically related to DENV, acute-phase
serum (or urine samples for Zika patients) of suspected cases was tested by 1) a DENV-CHIKV-
ZIKV multiplex real-time RT-PCR (rRT-PCR) (16,17) or 2) a ZIKV singleplex rRT-PCR (18)
alongside a pan-DENV and CHIKV rRT-PCR (19). Paired acute and convalescent serum samples
from suspected Zika cases were also tested by a validated algorithm consisting of five serological
assays (7,20).

Statistical analysis

To examine variation in the prevalence of 30 selected clinical findings, we calculated disease-specific prevalence estimates and pairwise prevalence differences across the three diseases. Prevalence-age trends (overall and stratified by sex) were estimated using logistic generalized additive models. Day-specific prevalences were also estimated. To compare the disease-specific temporal dynamics of fever, we estimated day-specific temperature means using linear mixed-effects models. We precluded medication-induced bias by excluding temperature data for individuals on antipyretics at the time of the medical consult, though the full temperature data was evaluated in a sensitivity analysis. Afebrile dengue cases were characterized by assessing their demographics, causative DENV serotype, temperature readings, and clinical profile during their medical visits. We developed machine learning models using boosted regression trees to classify diseases based on our selected clinical findings and to identify the most important distinguishing clinical features. We trained models on individual-level data across days 1-10 of illness with each clinical feature used as a binary variable and then predicted the probability of a case being assigned to a specific disease, using misclassifications as measures of disease similarity. Two separate sensitivity analyses examined classification performance on 1) reduced models using all 30 clinical feature data across only days 1-3 of illness and on 2) reduced models built from data across days 1-10 of illness that excluded all five laboratory findings. Continuous outcome data were compared first with Kruskal-Wallis rank sum tests and then Dunn tests with Hochberg corrections for multiple comparisons. The appendix (pp 2-5) contains additional information on all aspects of study methodology.

Role of the funding source

The study sponsors had no role in the study design; collection, analysis, and interpretation of data; or writing of this report. The corresponding author had full access to all study data and had final responsibility in deciding to submit the paper for publication.

RESULTS

From January 19, 2006, through December 31, 2023, 1,321 dengue, 517 chikungunya, and 522 Zika cases were identified (Table 1). Substantial numbers of dengue cases occurred most years, whereas chikungunya and Zika cases were concentrated in 2014-2015 and 2016, respectively (Figure S1; appendix p 15). We also detected 89 flavivirus cases (participants with DENV or ZIKV infections that could not be unambiguously distinguished by laboratory testing). Of these, 84 occurred when only DENV was circulating in Managua; we thus classified them as dengue cases.

The five remaining flavivirus cases and five co-infected cases were excluded from all analyses.

Among 1,405 (1,321+84) total dengue cases, 255 (18·1%) were caused by DENV-1, 425 (30·2%)

by DENV-2, 306 (21·8%) by DENV-3, and 191 (13·6%) by DENV-4.

The study sample contained 1,980 unique participants who experienced 2,444 illness episodes

and had 9,087 medical consults by HCSVF physicians (Table 1). Approximately 50·0% of all

cases were female. Children 10-14 years-old constituted the largest age group. Dengue cases

had significantly more clinical findings than chikungunya (p<0.0001) or Zika (p<0.0001) and more

medical consults (p<0.0001 and p<0.0001, respectively). In addition, 31·7% (446/1,405) of

dengue cases were referred to the hospital, in contrast to only 8·1% (42/517, p<0.0001) of

chikungunya and 0·2% of Zika (1/522, p<0.0001) cases. Chikungunya cases reported significantly

earlier to the HCSFV than dengue (p<0.0001) and Zika (p=0.0003) cases.

We first assessed the prevalence of clinical findings across diseases. Dengue cases frequently

exhibited fever (95·6%, 1,343/1,405), lymphocytopenia (83·4%, 1,158/1,405), headache (75·4%,

1,060/1,405), and leukopenia (71·8%, 997/1,405) (Table 2). Fever (100·0%, 517/517), arthralgia

(86·3%, 446/517), lymphocytopenia (85·6%, 441/517), and headache (76·6%, 396/517) were the

most common clinical features for chikungunya patients. Rash (79·5%, 415/522), specifically

generalized rash (73·9%, 386/522), was the only clinical feature occurring in ≥70·0% of Zika

cases. Fever was always present for chikungunya and the vast majority of dengue cases since

we did not test participants with afebrile rash until the Zika epidemic started in 2016.

Large and significant differences in the prevalence of many clinical findings were observed across

diseases (Tables 1, S1; Figure S2; appendix pp 6, 16). The largest differences were observed for

arthralgia, which was 62·7 (95% CI: 57·8, 67·2) and 47·8 (95% CI: 43·8, 51·6) percentage points

higher among chikungunya than Zika and dengue cases, respectively (*i.e.*, the prevalence of

arthralgia was 86·3% for chikungunya and 23·6% for Zika cases, so the difference was 62·7

percentage points). The prevalence of myalgia, fever, headache, and lymphocytopenia were all

~40·0 percentage points higher among chikungunya than Zika cases. Rash was 41·7 (95% CI:

37·3, 45·8) percentage points higher among Zika than dengue cases. Conversely, headache,

fever, myalgia, leukopenia, hemorrhagic manifestations, lymphocytopenia, and basophilia were

30·0-40·0 percentage points higher among dengue than Zika cases. Based on absolute and

relative differences in prevalence, dengue was most distinguished from chikungunya and Zika

based on the presence of basophilia, monocytopenia, and abdominal pain; chikungunya was most

distinguished by the presence of arthralgia and absence of papular rash and conjunctival injection;

Zika was most distinguished by the presence of generalized, erythematous rash and the absence

of fever, headache, myalgia, and lymphocytopenia (Tables 1, S1-2; appendix pp 6-11).

Several clinical findings occurred ~0·0% of the time, which can aid in excluding diseases during

differential diagnosis. For example, papular rash was observed in 0·4% (2/517) of chikungunya

cases, compared to 22·2% (116/522) of Zika cases and 7·5% (105/1,405) of dengue cases (Table

1); conjunctival injection displayed a similar pattern. Abdominal pain, thrombocytopenia, and

monocytopenia were rare for chikungunya and Zika cases ($\leq$3·3% prevalence) but were more

common (11·4-24·1%) among dengue cases.

We compared the age-varying presentation of clinical profiles that we use for laboratory testing.

As age increased, a growing percentage of dengue, chikungunya, and Zika cases met the 1997

WHO case definition for dengue (Figure S3; appendix p 17). Conversely, the percentage

exhibiting undifferentiated fever decreased with age across diseases. Zika cases were

significantly more likely to exhibit afebrile rash than dengue cases at any age.

We then examined the age-prevalence trends of the underlying clinical features and found many

significant differences (Figure 1). For example, the prevalence of leukopenia was >25·0

percentage points higher among dengue than Zika cases at every age, confirming earlier findings

(Table 1). We also found disease-specific age patterns. Uniquely among dengue cases, the

prevalence of all types of rash decreased linearly and nausea increased linearly by age.

Additionally, the prevalence of basophilia was constant and high (52·4-66·8%) for dengue cases,

in contrast to rapid age-based waning for chikungunya and Zika cases. Among chikungunya

cases, the prevalence of generalized, erythematous rash decreased from ages 2-10 but then

rebounded and continued increasing throughout adolescence. Among Zika cases, the prevalence

of fever increased with age and the prevalence of lymphocytopenia decreased before rebounding

in adolescence. Age-prevalence trends did not differ by sex (Figure S4; appendix p 18).

Significant differences were found after analyzing the data across the first 10 days of illness

(Figure 2). For example, the prevalence of fever decreased below 50·0% for Zika cases on day

three (88/177, 49·7%) and chikungunya cases on day four (46/122, 37·7%); dengue cases

achieved this on day six (137/555, 24·7%). Rash was most commonly observed among Zika

cases, particularly on days 1-4. In contrast, among chikungunya cases, the prevalence of

generalized rash increased from 11·2% (9/80) on day five to 41·5% (22/53) on day six and 47·2%

(17/36) before decreasing again; a similar pattern was observed for erythematous rash. Arthralgia

was most prevalent on days 1-4 among the chikungunya cases. Compared to dengue and

chikungunya cases, headache was about half as prevalent among Zika cases during days 1-2 of

illness.

Unlike dengue and chikungunya cases, which exhibited steady increases in the prevalence of

leukopenia until peaking on day five (dengue 517/702, 73·6%; chikungunya 27/37, 73·0%), the

average prevalence of leukopenia was relatively stable at 32·4% (315/971 medical records) for

Zika cases across days 1-7. The prevalence of basophilia was similar and low (~10·0%) across

diseases on days 1-3. Afterward, its average prevalence increased slightly to plateau at ~27·2%

(89/327 medical records) during days 4-7 of acute Zika illness. For dengue and chikungunya

cases, conversely, the prevalence of basophilia substantially increased, exceeding 75·0% by day

seven (dengue 190/229, 83·0%; chikungunya 7/9, 77·8%).

We then examined temperature readings taken at the HCSFV among cases not on antipyretic

medication (n=1,833) (Table S3; appendix p 12). In general, temperature dynamics for dengue

and chikungunya cases were more similar to each other than to Zika cases, though all three

dynamics exhibited unique characteristics. Average temperatures were highest on day one across

the three diseases (Figure S5; appendix p 19). While an average of 73·7% of day one

temperatures for dengue (99/140) and chikungunya (66/86) cases were $\geq$38·0°C (100·4°F), our

fever threshold, only 31·6% (12/38) of comparable Zika temperatures were $\geq$38·0°C. Indeed, Zika

cases had mean temperatures <38·0°C across days 1-10. Only 0·1% (7/5,118) of temperature

readings not influenced by antipyretics were $\geq$40·0°C (104·0°F), and all occurred among dengue

cases.

Average fevers for dengue and chikungunya cases were significantly higher, by 0·5-0·9°C (0·9-

1·6°F), than Zika cases during days 1-3 (dengue vs. Zika: day one, p<0.0001; day two, p<0.0001;

day three, p<0.0001; chikungunya vs. Zika: day one, p<0.0001; day two, p<0.0001; day three,

p<0.0001). By day three, average temperatures for Zika cases returned to the interquartile range

of healthy temperatures for this pediatric population (36·7-37·0°C, 98·0-98·6°F); for chikungunya

and dengue cases, this occurred on days five and six, respectively. On days 4-5, fever tended to

be more common among dengue than chikungunya (day four, p=0·068; day five, p=0·046) and

Zika (day four p<0.0001; day five p=0·014) cases. As a sensitivity analysis, we analyzed the full

temperature data, including participants both off and on antipyretics at the time of the medical

consults (Figure S6; appendix p 20). Results were very similar between the sensitivity and main

analyses.

We identified 62 dengue cases who neither reported recent histories of fever or feverishness nor

met the 38·0°C fever threshold. These cases had a median of two (IQR: 2, range: 1-9) medical

consults over days 1-10 of illness. Among the 36 females and 26 males, the average age was 9·5

years (SD=3·0). These cases represent 4·4% of all dengue cases (n=1,405) and 7·1% of dengue

cases since we began testing patients exhibiting afebrile rash for DENV infection (n=873). Nine

afebrile dengue cases were rRT-PCR-confirmed and caused by DENV-2. The vast majority of

afebrile dengue cases (56/62, 90·3%) occurred after 2016, when ZIKV was no longer circulating

in Managua (as determined by extensive testing in the PDCS and in Managua by public health

authorities). The maximum recorded temperature across the 62 cases was 37·5°C (99·5°F)

(Figure S7; appendix p 21). Fifty-three (85·5%) afebrile dengue cases first reported to HCSFV

within days 1-2 of illness, when temperatures for febrile dengue cases are at their highest (Figure

S5; appendix p 19). If fever were instead defined as ≥ 1 temperature measurement >37·2°C

(99·0°F), as is sometimes done for children, 44 dengue cases would still be considered afebrile.

Most afebrile dengue cases were very mild and required no hospitalization referrals (Table S4;

appendix p 13). However, five (8·1%) exhibited dengue warning signs, as defined by WHO in

2009 (4), with one warning sign each (two with mucosal bleeding, two with abdominal pain, one

with persistent vomiting). Of the 62 cases, 12 (19·4%) had no clinical findings besides rash, and

17 (27·4%) exhibited only one clinical finding besides rash, predominantly (12/17, 70·6%)

leukopenia. Rash was almost always erythematous and generalized. Afebrile dengue cases had

significantly fewer per-case medical consults than febrile dengue cases (2·2 vs. 4·9, p<0.0001),

and they most closely resembled afebrile Zika cases in terms of per-case medical consults (2·2

vs. 1·8, p=0·19), day of first medical consult (1·7 vs. 1·7, p=1·00), and number of clinical findings

exhibited over the first 3 (2·5 vs. 2·3, p=0·67) and 10 days of illness (2·7 vs. 2·6, p=0·81).

Finally, we developed machine learning models that classified cases based on the 30 selected

clinical findings. In general, the full models covering days 1-10 of illness had high specificity

(88·8%-96·0%) and more moderate sensitivity (68·2%-86·1%) (Figure 3). The full chikungunya

model correctly classified 72·5% (95% CI: 68·5, 76·2) of chikungunya cases and had a very low

level ($\leq 3\cdot 0\%$) of misclassification for most of the six types of non-chikungunya cases (*i.e.*, overall,

febrile, and afebrile dengue and Zika cases) (Figure 3A). The presence of arthralgia and absence
of basophilia and leukopenia were the most important predictors of chikungunya vs. non-
chikungunya disease status (Figure 3B). The full dengue model correctly classified 86·1% (95%
CI: 84·0, 87·8) of all dengue cases. It correctly classified a much higher percentage of febrile
(89·6%; 95% CI: 87·7, 91·2) than afebrile (15·0%; 95% CI: 7·9, 26·3) dengue cases, confirming
our earlier findings that afebrile and febrile dengue present very differently. The full dengue model
misclassified 18·1% (95% CI: 14·2, 22·7) of febrile Zika cases as dengue. The dengue model's
most important predictors were the presence of basophilia and leukopenia (Figure 3C). The full
Zika model correctly classified 68·2% (95% CI: 64·1, 72·1) of all Zika cases. In contrast to the
dengue model, the Zika model correctly classified a higher percentage of afebrile (99·1%; 95%
CI: 96·4, 100·0) than febrile (47·1%; 95% CI: 41·66, 52·7) Zika cases. Across all types of cases,
the greatest percentage of misclassification was observed with the Zika model's misclassification
of 78·3% (95% CI: 66·2, 87·0) of afebrile dengue cases as Zika, confirming our earlier findings
that afebrile dengue and afebrile Zika cases present very similarly. The absence of fever was
most indicative of Zika vs. non-Zika status (Figure 3D).
399
400   All three full models had increasing sensitivity with increasing pediatric age (Figure S8; appendix
401   p 22). The chikungunya model had modest (~50·0%) sensitivity in early childhood, likely because
402   arthralgia, the model's most important variable, was absent or difficult to diagnose in ~25·0% of
403   young children (Figure 1).
404
We constructed two sets of reduced classification models as a sensitivity analysis. The first set
included all 30 variables but only through days 1-3 of illness, mirroring the diagnostic process
during early acute illness. This first set of reduced models broadly resembled but exacerbated the
weaknesses (*i.e.*, incorrect predictions) of their respective full models (Figures S9-10; appendix
pp 23-24). For example, the reduced chikungunya model correctly classified 28·8% (vs. 45·0% in
the full model) of the youngest chikungunya cases. The reduced dengue model misclassified a
greater proportion of febrile Zika cases (26·6% vs. 18·1% in the full model); similarly, the reduced
Zika model misclassified a greater proportion of afebrile dengue cases (91·2% vs. 78·3% in the
full model). The diminished performance of the first set of reduced models is likely attributable to
the loss of information from clinical findings that only differ significantly in prevalence after days
1-3 of illness (Figure 2).
416

The second set of reduced models included data across days 1-10 of illness but excluded
laboratory findings (*i.e.*, leukopenia, thrombocytopenia, lymphocytopenia, monocytopenia, and
basophilia), mirroring health settings without access to laboratory resources. For this set of
models, the most noticeable difference was the decreased sensitivity of the dengue (76·8% vs.
86·1% in the full model) and Zika models (56·5% vs. 68·2% in the full model) (Figures S11-12;
appendix pp 25-26). This diminished performance suggests that laboratory variables are
especially important for distinguishing dengue from Zika cases.
424

DISCUSSION

In contrast to many existing studies that separately document the clinical presentation of dengue,
chikungunya, or Zika cases across distinct populations, this study analyzed clinical manifestations
of the three diseases within a single long-running pediatric cohort. We leveraged our prospective
study design, broad laboratory testing criteria, and extensive clinical records to elucidate
differences in disease presentation across days 1-10 of illness. We performed the most
comprehensive analysis of afebrile dengue cases to date, and we used machine learning to
classify cases based on clinical findings. Our conclusions are strengthened by direct comparisons
of clinical features across dengue, chikungunya, and Zika, which only occurred in one (9) of the
80 studies summarized in PAHO's report on diagnostic guidelines (8). Further, this one report
focused mostly on adults and was ~10 times smaller than our current study. In our review of the
literature, we found no pediatric cohort that simultaneously compared the presentation of dengue,
chikungunya, and Zika. Thus, our study meets an urgent need to identify meaningful differences
across these three diseases in one well-characterized pediatric population.
439

The PAHO report suggested using the occurrence of thrombocytopenia, leukopenia, and
progressive increases in hematocrit to distinguish dengue; arthralgia to distinguish chikungunya;
and pruritus to distinguish Zika. Our findings agree with the use of thrombocytopenia, leukopenia,
and arthralgia. We further identified several other key distinguishing features, especially at
particular ages and days of illness (Table 3), that may aid diagnosis and case management. Both
the PAHO report and our findings concur that complete blood counts are important sources of
certain highly discriminating clinical features.
447

448   We developed classification models to algorithmically replicate the process of differential
449   diagnosis. This allowed us to quantify the performance of modern approaches to this difficult
450   analytical task and to identify the most important predictors of each disease. In general, our

classification models performed well; however, the specific weaknesses of each model imply that no set of our selected clinical features can classify cases without some moderate degree of error due to the irreducible overlap in clinical presentation of the three diseases. Thus, our models are not intended to be used in clinical practice. Nevertheless, because our analytical approach is tailored to the classification problem, our modeling results do identify meaningfully distinguishing features of each disease. Moreover, our estimates of the models' performance quantify how well it is possible to classify cases in a primary care setting without rapid or laboratory tests, which is a very common scenario for health settings in resource-limited, arbovirus-endemic areas.

Our machine learning model reliably distinguished chikungunya from dengue and Zika cases, irrespective of fever status, though its sensitivity was muted among young children. While the dengue model captured most febrile dengue cases, it classified 18% of febrile Zika and only 15% of afebrile dengue cases as dengue. The dengue model's poor ability to identify afebrile dengue cases likely stemmed from their scarcity in the dataset as well as their non-specific and minimal clinical presentation. Interestingly, the most important predictor of dengue was basophilia. As it is not known to play a role in dengue pathogenesis, our study only establishes basophilia as a biomarker for dengue. The Zika model correctly classified 99% of afebrile Zika cases, but it also misclassified 78% of afebrile dengue cases as Zika, further showcasing their clinical similarity. Thus, afebrile dengue and afebrile Zika cases are only distinguishable by definitive laboratory testing. The diminished performance of the classification models using data only from days 1-3 of illness suggests that resource-limited settings experiencing concurrent epidemics can reduce diagnostic uncertainty by prioritizing cases in early illness for laboratory testing. Doing so also enables timelier management of severe complications, particularly for dengue.

In 1952, following intentional DENV infection of human volunteers (21), Sabin first reported mild cases of afebrile dengue with rash and leukopenia, the most common presentation of our afebrile dengue cases. While our 62 afebrile dengue cases were generally mild, five exhibited warning signs. Moderate-to-severe afebrile dengue has been reported from surveillance (22) and hospital (23–26) data. In the PDCS, 7·1% of captured dengue cases were afebrile after we began testing cases exhibiting afebrile rash. This percentage is higher than other studies documenting afebrile dengue (22–29), probably because only our study systematically tested afebrile cases for many years. However, 7·1% likely represents a *lower bound* on the hidden magnitude of afebrile dengue because afebrile cases without rash have been reported (26,28,29). Importantly, afebrile dengue

has been observed in DENV-2 cases and in DENV-1 and DENV-4 outbreaks (27), so most, if not

all, serotypes can cause afebrile dengue.

Since the WHO (1997 and 2009) and PAHO (2023) dengue case definitions require fever (3–5),

the existence of afebrile dengue complicates diagnosis, treatment, surveillance, risk assessments

for severe manifestations upon a secondary DENV infection, and transmission or epidemiological

studies. For example, key outbreak parameters, like R_0, are likely systematically underestimated

by not considering afebrile cases. Consequently, afebrile dengue should be considered in future

diagnostic guidelines for dengue, and further studies on its epidemiological, immunological, and

clinical aspects are warranted. As we have previously shown for Zika (7), the spectrum of some

flaviviral diseases is wider, but less febrile, than traditionally understood, resulting in diminished

sensitivity of the case definitions.

Systematic collection of medical data in a single population, large sample sizes, and modern

analytic methods strengthened our study. We were limited by our testing criteria, which prevented

cases of afebrile dengue and potentially afebrile chikungunya from being captured before 2016.

However, our criteria reflected contemporaneous knowledge about disease presentation.

Moreover, analyzing the full complexities of dengue (*e.g.,* comparisons of multiple DENV

serotypes, primary vs. secondary infections, severe vs. non-severe manifestations) was beyond

the scope of this study; however, these aspects are explored in depth in our companion paper

focusing only on dengue cases using data from our hospital-based study and community-based

cohort study over 19 years (30). Per clinical guidelines from the Nicaraguan Ministry of Health,

dengue patients are referred for hospitalization at the first indication of a warning sign of disease

severity. These guidelines went into effect in 2009 and precluded us from observing the full range

of dengue severity in our study sample, which is based exclusively at a primary health center.

Nevertheless, there was enough variation in the presentation of our dengue cases to establish

how the disease tends to manifest differently than chikungunya and Zika in children. All of our

participants were of similar race and ethnicity, which prevented us from examining if disease

manifestations differed by racial and ethnic categories. Finally, because the HCSFV is primarily

an outpatient clinic, PDCS cases are not under constant medical observation throughout the

duration of their acute illness. As a result, new clinical features may have arisen during days when

the cases did not report to the HCSFV for additional medical care. However, surveys of PDCS

participants (10) reveal that only 4·9% of cases either consult non-PDCS medical personnel or

do not consult any medical personnel when clinical features arise, indicating high participant
compliance with our study protocol.
519
In summary, we showed that pediatric dengue, chikungunya, and Zika tend to manifest differently
overall, by age, and by day of illness. While there is much overlap in the presentation of the three
diseases, exploiting the many differences we identified can enable more reliable diagnoses and
better case management in the absence of confirmatory laboratory methods. Our afebrile dengue
cases, particularly those with warning signs, emphasize that this under-characterized
presentation of dengue should be incorporated into future guidance. With climate change
accelerating the threat posed by mosquito-borne diseases (2), updated knowledge will allow for
improved diagnostic, surveillance, and research endeavors.

AUTHOR CONTRIBUTIONS

FABC and EH conceived the study. AB, AG, GK, and EH developed the study design. SO, NS, MP, AB, and GK implemented the study design and collected data. AB oversaw the laboratory testing that was performed by DC, TM, and SS. BLM, JCM, SA, LC, and ZC organized and verified the data. FBC analyzed the data and performed the statistical analyses, with CJC consulting on the machine learning models. FABC and EH drafted and revised the manuscript, and all authors reviewed the manuscript.

DECLARATION OF INTERESTS

All authors declare no competing interests.

ACKNOWLEDGMENTS

We are deeply grateful to our study team at the Centro de Salud Sócrates Flores Vivas, the Laboratorio Nacional de Virología at the Centro Nacional de Diagnóstico y Referencia, and the Sustainable Sciences Institute in Nicaragua. Most importantly, we sincerely thank the PDCS study participants and their families for engaging with us in the enterprise of science. This study was supported by grants R01 AI099631 (AB), P01 AI106695 (EH), U01 AI153416 (EH), and U19 AI118610 (EH) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Additional support for the PDCS (2004-2015) was obtained from grant VE-1 (PDVI) from the Bill and Melinda Gates Foundation as well as the FIRST grant from the Bill and Melinda Gates Foundation and the Instituto Carlos Slim de la Salud. CJC was supported by the US National Science Foundation (NSF DBI 2213854).

ETHICS STATEMENT

Institutional Review Boards of the University of California, Berkeley, the University of Michigan, and the Nicaraguan Ministry of Health approved the Pediatric Dengue Cohort Study (PDCS) protocol. Participants' parents or legal guardians provided written informed consent. Participants ≥6 years old provided verbal assent.

REFERENCES

1. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus. PLoS Negl Trop Dis. 2012 Aug;6(8):e1760--e1760.

2. Ryan SJ, Carlson CJ, Mordecai EA, Johnson LR. Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. Han BA, editor. PLoS Negl Trop Dis. 2019 Mar 28;13(3):e0007213.

3. World Health Organization. Dengue haemorrhagic fever: Diagnosis, treatment, prevention, and control. 2nd ed. Geneva; 1997.

4. World Health Organization. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control (New Edition 2009). World Health Organization; 2009. 158 p.

5. Pan American Health Organization. Case definitions, clinical classification, and disease phases: Dengue, Chikungunya, and Zika. Washington, DC; 2023.

6. Warnes CM, Andres F, Carrillo B, Zambrana JV, Mercado BL, Arguello S, et al. Longitudinal analysis of post-acute chikungunya-associated arthralgia in children and adults: A prospective cohort study in Managua, Nicaragua (2014–2018). Abu Kassim NF, editor. PLoS Negl Trop Dis. 2024 Feb 28;18(2):e0011948.

7. Burger-Calderon R, Bustos Carrillo F, Gresh L, Ojeda S, Sanchez N, Plazaola M, et al. Age-dependent manifestations and case definitions of paediatric Zika: a prospective cohort study. Lancet Infect Dis. 2020 Dec;20(3):371–80.

8. PAHO. Guidelines for the clinical diagnosis and treatment of dengue, chikungunya, and Zika. Washington, D.C.: Pan American Health Organization; 2022.

9. Waggoner JJ, Gresh L, Vargas MJ, Ballesteros G, Tellez Y, Soda KJ, et al. Viremia and clinical presentation in Nicaraguan patients infected with Zika virus, chikungunya virus, and dengue virus. Clin Infect Dis. 2016 Dec 15;63(12):1584–90.

10. Kuan G, Gordon A, Aviles W, Ortega O, Hammond SN, Elizondo D, et al. The Nicaraguan Pediatric Dengue Cohort Study: Study design, methods, use of information technology, and extension to other infectious diseases. Am J Epidemiol. 2009 Jul 1;170(1):120–9.

11. Kuan G, Ramirez S, Gresh L, Ojeda S, Melendez M, Sanchez N, et al. Seroprevalence of anti-chikungunya virus antibodies in children and adults in Managua, Nicaragua, after the first chikungunya epidemic, 2014-2015. Bingham A, editor. PLoS Negl Trop Dis. 2016 Jun 20;10(6):e0004773.

12. Zambrana JV, Bustos Carrillo F, Burger-Calderon R, Collado D, Sanchez N, Ojeda S, et

al. Seroprevalence, risk factor, and spatial analyses of Zika virus infection after the 2016
epidemic in Managua, Nicaragua. Proc Natl Acad Sci. 2018 Sep 11;115(37):9294–9.

13.   World Health Organization. Proposed case definition of chikungunya fever (WHO,
SEARO). 2008.

14.   PAHO/WHO. Zika resources: Case definitions [Internet]. 2016. Available from:
https://www.paho.org/hq/index.php?option=com_content&view=article&id=11117:zika-
resources-case-definitions&Itemid=41532&lang=en

15.   WHO. Zika virus disease | Interim case definition [Internet]. World Health Organization;
2016. Available from: https://www.who.int/csr/disease/zika/case-definition/en/

16.   Waggoner JJ, Gresh L, Mohamed-Hadley A, Ballesteros G, Davila MJV, Tellez Y, et al.
Single-reaction multiplex reverse transcription PCR for detection of Zika, chikungunya, and
dengue viruses. Emerg Infect Dis. 2016 Jul;22(7):1295–7.

17.   Santiago GA, Vázquez J, Courtney S, Matías KY, Andersen LE, Colón C, et al.
Performance of the Trioplex real-time RT-PCR assay for detection of Zika, dengue, and
chikungunya viruses. Nat Commun. 2018 Dec 11;9(1):1391.

18.   Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. Genetic and
serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia,
2007. Emerg Infect Dis. 2008 Aug;14(8):1232–9.

19.   Waggoner JJ, Ballesteros G, Gresh L, Mohamed-Hadley A, Tellez Y, Sahoo MK, et al.
Clinical evaluation of a single-reaction real-time RT-PCR for pan-dengue and chikungunya
virus detection. J Clin Virol. 2016 May;78:57–61.

20.   Gordon A, Gresh L, Ojeda S, Katzelnick LC, Sanchez N, Mercado JC, et al. Prior dengue
virus infection and risk of Zika: A pediatric cohort in Nicaragua. von Seidlein L, editor. PLOS
Med. 2019 Jan 22;16(1):e1002726.

21.   Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg. 1952;1(1):30–
50.

22.   Tukasan C, Furlan NB, Estofolete CF, Nogueira ML, da Silva NS. Evaluation of the
importance of fever with respect to dengue prognosis according to the 2009 WHO
classification: A retrospective study. BMC Infect Dis. 2017 Jan 4;17(1):1–6.

23.   Amâncio FF, Heringer TP, De Oliveira CDCHB, Fassy LB, De Carvalho FB, Oliveira DP,
et al. Clinical profiles and factors associated with death in adults with dengue admitted to
intensive care units, Minas Gerais, Brazil. PLoS One. 2015 Jun 19;10(6):e0129046.

24.   Méndez-Domínguez N, Achach-Medina K, Morales-Gual YM, Gómez-Carro S. Dengue,
presentación inusual en un lactante. Reporte de un caso. Rev Chil Pediatr.

626   2017;88(2):275–9.

627 25. Badreddine S, Al-Dhaheri F, Al-Dabbagh A, Al-Amoudi A, Al-Ammari M, Elatassi N, et al.
628   Dengue fever: Clinical features of 567 consecutive patients admitted to a tertiary care
629   center in Saudi Arabia. Saudi Med J. 2017 Oct 1;38(10):1025–33.

630 26. Bhat D. The silent threats of afebrile dengue. Int J Med Sci Curr Res. 2024;7(4):449–53.

631 27. Yoon I-K, Rothman AL, Tannitisupawong D, Srikiatkhachorn AA, Jarman RG, Aldstadt J,
632   et al. Underrecognized mildly symptomatic viremic dengue virus infections in rural Thai
633   schools and villages. J Infect Dis. 2012 Aug 1;206(3):389–98.

634 28. Yasri S, Wiwanitkit V. Afebrile dengue myositis. Ann Trop Med Public Heal. 2016;9(5):360.

635 29. Knot W, Gupta N, Khatiwada S, Goyal A, Das R, Brijwal M, et al. A curious case of afebrile
636   dengue. J Assoc Physicians India. 2018 Aug;66(8):89–90.

637 30. Narvaez F, Montenegro C, Juarez JG, Zambrana JVJV, Gonzalez K, Videa E, et al.
638   Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in
639   Nicaragua. Marques ETA, editor. PLoS Negl Trop Dis. 2025 Jan 10;19(1):e0012811.

TABLES

Table 1. Characteristics of the dengue, chikungunya, and Zika cases in the PDCS in Managua, Nicaragua, by disease (January 2006 – December 2023).

	Dengue N (%)	Chikungunya N (%)	Zika N (%)
Overall	1,405 (100·0)	517 (100·0)	522 (100·0)
Epidemic years	Most years	2014 and 2015	2016
Sex			
Male	666 (47·4)	265 (51·3)	234 (44·8)
Female	739 (52·6)	252 (48·7)	288 (55·2)
Age[1]			
Mean (SD); median (IQR)	10·3 (3·5); 10·5 (5·4)	9·6 (3·5); 10·2 (5·8)	8·7 (3·6); 8·7 (5·7)
2-4 years	105 (7·5)	70 (13·5)	104 (19·9)
5-9 years	531 (37·8)	182 (35·2)	220 (42·1)
10-14 years	640 (45·6)	265 (51·3)	198 (37·9)
15-17 years	129 (9·2)	0 (0·0)	0 (0·0)
White race[2]	1,405 (100·0)	517 (100·0)	522 (100·0)
Hispanic ethnicity[2]	1,405 (100·0)	517 (100·0)	522 (100·0)
RT-PCR confirmed[3]	1,180 (84·0)	510 (98·6)	350 (67·0)
Mean day of first presentation to the health center per case (SD); median (IQR)[4]	2·0 (1·1); 2·0 (1·0)	1·7 (0·8); 2·0 (1·0)	1·9 (0·8); 2·0 (1·0)
Mean number of medical consults per case (SD); median (IQR)[5]	4·8 (3·6); 4·0 (4·0)	2·4 (1·3); 2·0 (2·0)	2·2 (1·1); 2·0 (2·0)

Mean number of clinical findings over days 1-10 of illness per case (SD); median (IQR)[6]	8·2 (3·3); 8·0 (4·0)	6·5 (2·1); 6·0 (3·0)	4·1 (2·3); 4·0 (3·0)
Mean number of clinical findings over days 1-3 of illness per case (SD); median (IQR)[7]	6·7 (2·9); 6·0 (3·0)	6·2 (2·0); 6·0 (3·0)	3·6 (2·0); 3·0 (3·0)
Referred to pediatric hospital[8]	446 (31·7)	42 (8·1)	1 (0·2)

[1] The PDCS expanded its age range from 2-14 years to 2-17 years in August 2018, after the chikungunya and Zika epidemics subsided. As a result, no chikungunya and Zika cases in the 15-17 year age range are included in the study. The mean (SD) age for dengue cases aged 2-14 (the same age range for the chikungunya and Zika cases) is 9.7 (3.1) years. The corresponding median is 10.0 years with an IQR of 4.9.

[2] Racial and ethnic categories reflect the classifications used by the US Census Bureau.

[3] DENV serotype information was not available for three of the dengue cases that were RT-PCR-positive.

[4] Chikungunya cases presented to the health center significantly earlier than dengue (p<0.0001) and Zika cases (p=0.0003). There was no evidence of a difference between dengue and Zika cases .

[5] Dengue cases had a significantly higher number of visits to the health center than chikungunya (p<0.0001) and Zika cases (p<0.0001). There was no evidence of a difference between chikungunya and Zika cases (p=0·26).

[6] Over the first ten days of illness, dengue cases had a significantly higher number of clinical findings than chikungunya (p<0.0001) and Zika cases (p<0.0001). Chikungunya cases had a significantly higher number of clinical findings than Zika cases (p<0.0001). Rash was considered collectively for this analysis; for example, if a child exhibited a rash that was both localized and macular, it was only counted once.

[7] Over the first three days of illness, Zika cases had a significantly fewer number of clinical findings than dengue (p<0.0001) and chikungunya cases (p<0.0001). There was no evidence of a difference between dengue and chikungunya cases (p=0·10). Rash was considered collectively for this analysis.

[8] Dengue cases were more often referred to the study hospital, Hospital Infantil Manuel de Jesús Rivera, a pediatric tertiary referral hospital, than chikungunya (p<0.0001) and Zika cases (p<0.0001). Chikungunya cases were more often referred to the study hospital than Zika cases (p<0.0001). A high percentage of dengue cases were referred for hospitalization because guidelines from the Nicaraguan Ministry of Health require a dengue case with any warning sign, per the 2009 WHO guidelines for dengue (5), to be referred for hospitalization.

671   Abbreviations: CHIKV, chikungunya virus; DENV, dengue virus; IQR, interquartile range; PDCS, Pediatric

672   Dengue Cohort Study; RT-PCR, reverse transcription polymerase chain reaction; SD, Standard deviation;

673   ZIKV, Zika virus

Table 2. Prevalence and prevalence differences across the first ten days of illness for dengue, chikungunya, and Zika cases in the PDCS.

Clinical finding	Dengue N (%)	Chikungunya N (%)	Zika N (%)	Dengue vs. Chikungunya PD (95% CI)[1]	Chikungunya vs. Zika PD (95% CI)[1]	Zika vs. Dengue PD (95% CI)[1]
Fever	1,343 (95·6%)	517 (100·0%)	310 (59·4%)	-4·4% (-5·6%, -3·5%)	40·6% (36·5%, 44·9%)	-36·2% (-40·6%, -31·9%)
Rash[2]	531 (37·8%)	281 (54·4%)	415 (79·5%)	-16·6% (-21·5%, -11·6%)	-25·1% (-30·6%, -19·6%)	41·7% (37·3%, 45·8%)
Arthralgia	540 (38·4%)	446 (86·3%)	123 (23·6%)	-47·8% (-51·6%, -43·8%)	62·7% (57·8%, 67·2%)	-14·9% (-19·2%, -10·3%)
Headache	1,060 (75·4%)	396 (76·6%)	195 (37·4%)	-1·2% (-5·3%, 3·3%)	39·2% (33·6%, 44·6%)	-38·1% (-42·7%, -33·3%)
Retro-orbital pain	378 (26·9%)	67 (13·0%)	37 (7·1%)	13·9% (10·1%, 17·5%)	5·9% (2·3%, 9·6%)	-19·8% (-22·9%, -16·5%)
Hemorrhagic manifestations[3]	444 (31·6%)	54 (10·4%)	15 (2·9%)	21·2% (17·4%, 24·6%)	7·6% (4·7%, 10·8%)	-28·7% (-31·5%, -25·8%)
Myalgia	527 (37·5%)	252 (48·7%)	47 (9·0%)	-11·2% (-16·2%, -6·2%)	39·7% (34·7%, 44·6%)	-28·5% (-31·9%, -24·8%)
Abdominal pain	338 (24·1%)	17 (3·3%)	4 (0·8%)	20·8% (18·0%, 23·4%)	2·5% (0·9%, 4·5%)	-23·3% (-25·7%, -20·9%)
Nausea	309 (22·0%)	24 (4·6%)	9 (1·7%)	17·4% (14·4%, 20·1%)	2·9% (0·8%, 5·3%)	-20·3% (-22·7%, -17·8%)
Vomiting	391 (27·8%)	49 (9·5%)	13 (2·5%)	18·4% (14·8%, 21·7%)	7·0% (4·2%, 10·0%)	-25·3% (-28·0%, -22·6%)
Pharyngeal erythema	646 (46·0%)	195 (37·7%)	108 (20·7%)	8·3% (3·3%, 13·1%)	17·0% (11·6%, 22·4%)	-25·3% (-29·5%, -20·8%)

Cervical lymphadenopathy	283 (20·1%)	47 (9·1%)	73 (14·0%)	11·1% (7·6%, 14·2%)	-4·9% (-8·8%, -1·0%)	-6·2% (-9·7%, -2·4%)
Conjunctival injection	214 (15·2%)	4 (0·8%)	48 (9·2%)	14·5% (12·4%, 16·5%)	-8·4% (-11·3%, -6·0%)	-6·0% (-9·0%, -2·7%)
Sore throat	272 (19·4%)	28 (5·4%)	46 (8·8%)	13·9% (11·0%, 16·7%)	-3·4% (-6·6%, -0·3%)	-10·5% (-13·6%, -7·2%)
Appetite loss	460 (32·7%)	134 (25·9%)	31 (5·9%)	6·8% (2·2%, 11·2%)	20·0% (15·7%, 24·3%)	-26·8% (-29·9%, -23·5%)
Cough	289 (20·6%)	53 (10·3%)	41 (7·9%)	10·3% (6·8%, 13·6%)	2·4% (-1·1%, 6·0%)	-12·7% (-15·7%, -9·4%)
Rhinorrhea	276 (19·6%)	44 (8·5%)	32 (6·1%)	11·1% (7·8%, 14·2%)	2·4% (-0·8%, 5·6%)	-13·5% (-16·3%, -10·4%)
Facial flushing	67 (4·8%)	74 (14·3%)	11 (2·1%)	-9·5% (-13·0%, -6·5%)	12·2% (9·1%, 15·7%)	-2·7% (-4·2%, -0·8%)
Diarrhea	76 (5·4%)	11 (2·1%)	8 (1·5%)	3·3% (1·4%, 4·9%)	0·6% (-1·1%, 2·4%)	-3·9% (-5·4%, -2·1%)
Erythematous rash	457 (32·5%)	231 (44·7%)	339 (64·9%)	-12·2% (-17·1%, -7·2%)	-20·3% (-26·1%, -14·3%)	32·4% (27·6%, 37·1%)
Generalized rash	463 (33·0%)	213 (41·2%)	386 (73·9%)	-8·2% (-13·2%, -3·4%)	-32·7% (-38·3%, -27%)	41·0% (36·4%, 45·3%)
Localized rash	119 (8·5%)	99 (19·1%)	43 (8·2%)	-10·7% (-14·5%, -7·2%)	10·9% (6·8%, 15·1%)	-0·2% (-2·8%, 2·8%)
Papular rash	105 (7·5%)	2 (0·4%)	116 (22·2%)	7·1% (5·6%, 8·6%)	-21·8% (-25·6%, -18·4%)	14·7% (11·1%, 18·7%)
Maculopapular rash[4]	71 (5·1%)	1 (0·2%)	102 (19·5%)	4·9% (3·7%, 6·2%)	-19·3% (-23·0%, -16·1%)	14·5% (11·1%, 18·3%)

Macular rash	176 (12·5%)	72 (13·9%)	182 (34·9%)	-1·4% (-5·0%, 1·9%)	-20·9% (-26·0%, -15·9%)	22·3% (18·0%, 26·8%)
Leukopenia	997 (71·8%)[5]	133 (25·8%)[8]	215 (41·2%)	46·0% (41·4%, 50·3%)	-15·4% (-21·0%, -9·7%)	-30·6% (-35·4%, -25·7%)
Thrombocytopenia	158 (11·4%)[5]	8 (1·6%)[8]	2 (0·4%)	9·8% (7·8%, 11·8%)	1·2% (0·0%, 2·7%)	-11·0% (-12·8%, -9·3%)
Lymphocytopenia	1,158 (83·4%)[5]	441 (85·6%)[8]	221 (42·3%)	-2·3% (-5·7%, 1·5%)	43·3% (38·0%, 48·4%)	-41·0% (-45·6%, -36·3%)
Monocytopenia	194 (16·8%)[6]	12 (2·3%)[8]	7 (1·3%)	14·4% (11·9%, 16·9%)	1·0% (-0·7%, 2·8%)	-15·4% (-17·8%, -13·0%)
Basophilia	590 (54·9%)[7]	60 (11·7%)[8]	120 (23.0%)	43·3% (39·1%, 47·2%)	-11·3% (-15·9%, -6·8%)	-31·9% (-36·5%, -27·1%)

[1] Positive differences indicate that the clinical finding was more prevalent among the first case group in the comparison, and vice versa. For example, fever was observed among 95·6% of the dengue cases and 100·0% of the chikungunya cases. Therefore, the prevalence difference is -4·4%.

[2] Rash refers to any kind of rash.

[3] Hemorrhagic manifestations were defined as spontaneous petechiae, purpura, ecchymosis, hematoma, hemoptysis, epistaxis, gingival bleeding, melena, hematemesis, hematuria, subconjunctival hemorrhage, menorrhagia or vaginal bleeding as observed by a study physician or reported by the patient, or positive tourniquet test.

[4] Maculopapular rash was defined as a rash that was both macular and papular during a single medical consult.

[5] Percentages calculated among 1,389 (98·9%) dengue cases where leukocyte, platelet, and lymphocyte counts were available.

[6] Percentages calculated among 1,158 (82·4%) dengue cases where monocyte counts were available.

[7] Percentages calculated among 1,074 (76·4%) dengue cases where basophil counts were available.

[8] Percentages calculated among 515 (99·6%) chikungunya cases where complete blood count data were available.

Abbreviation: CI, confidence interval; PD, prevalence difference; PDCS, Pediatric Dengue Cohort Study

690 **Table 3.** Most distinguishing clinical characteristics of dengue, chikungunya, and Zika cases in the PDCS

691 in Managua, Nicaragua, by disease (January 2006 – December 2023).[1,2]

	Dengue	Chikungunya	Zika
The most distinguishing clinical features based on presence	Monocytopenia	Arthralgia (days 1-4)	Generalized rash (days 1-4)
	Abdominal pain	Facial flushing	Erythematous rash (days 1-4)
	Thrombocytopenia (days 5-7)	Localized rash	Maculopapular rash (days 1-4)
	Nausea		
	Hemorrhagic manifestations (days 2-6)		
	Vomiting		
	Basophilia (>age 5)		
	Leukopenia		
	Sore throat (age 2-5)		
	Retro-orbital pain		
The most distinguishing clinical features based on absence	Rash (days 1-3 and >age 13)	Papular rash	Fever (days 1-3)
		Maculopapular rash	Lymphocytopenia (>age 4 and days 1-6)
		Conjunctival injection	Headache (days 1-2)
		Basophilia	Myalgia (days 1-3)
		Leukopenia	Appetite loss
			Pharyngeal erythema (age 2-10)

[1] Data in the table summarize our results examining the prevalence of clinical features overall, by age, and

by days of illness, as well as the results of the classification models. Clinical features had to consistently

differ across multiple analyses to be placed in this summary table. The information in parentheses indicates

ages (in years) and days of illness where the presence or absence of the corresponding clinical feature is

especially pronounced.

[2] While differences in the temporal dynamics of fever do not fit neatly into this table, we note that average

temperatures among Zika cases not on antipyretics were sub-febrile across days 1-10 of illness; average

temperature for dengue, chikungunya, and Zika cases returned to normal on days six, five, and three,

respectively; and fever tended to be more prevalent among dengue cases than chikungunya and Zika cases

on days 4-5 of illness.

Abbreviation: PDCS, Pediatric Dengue Cohort Study

 FIGURE LEGENDS

Figure 1. Age-prevalence trends for clinical features among the dengue, chikungunya, and
Zika PDCS cases in Managua, Nicaragua (2006-2023). The solid lines indicate the point
estimate of the average, and the shaded area indicates its 95% confidence band. Trends were
estimated with logistic generalized additive models. A clinical finding was considered present if a
case reported experiencing it during the first 10 days of illness. For this figure only, we changed
the data of five chikungunya cases to not have fever to prevent a model convergence error, as a
meaningful 95% confidence band could not be estimated in the presence of all chikungunya
cases' exhibiting fever (as was reported).

Figure 2. The prevalence of clinical features by disease and day of illness in the PDCS in
Managua, Nicaragua (2006-2023). Dots show the day-specific average and the vertical bars
correspond to its Agresti-Coull 95% confidence interval. A clinical finding was considered present
if a case reported experiencing it during a given day within the first 10 days of illness. Exceedingly
few chikungunya and Zika cases had blood samples taken on days 8-10 of illness. We therefore
removed the unreliable point and interval estimates for leukopenia, thrombocytopenia,
lymphocytopenia, monocytopenia, and basophilia for these days.

Figure 3. Machine learning model results for PDCS cases in Managua, Nicaragua (2006-
2023). (A) Three separate models were constructed to classify, based on the 30 evaluated clinical
findings from days 1-10 of illness, dengue from chikungunya and Zika (the dengue model),
chikungunya from dengue and Zika (the chikungunya model), and Zika from dengue and
chikungunya (the Zika model). The values shown indicate the percentage of true cases (y-axis)
that were classified as a given disease by the disease-specific model (x-axis). For example,
72·5% of chikungunya cases were classified as chikungunya cases by the chikungunya model,
and 2·8% of all dengue cases were classified as chikungunya cases by the chikungunya model.
Percentages in panel A that are bold and underlined denote correct classifications (which an ideal
classifier maximizes), and those in regular font represent incorrect classifications (which an ideal
classifier minimizes). Percentages in parentheses denote 95% confidence intervals. Model results
are reported for all three diseases as well as by fever status for dengue and Zika cases. The
chikungunya model had a sensitivity of 72·5% (95% CI: 68·5, 76·2) and an overall specificity of
96·0 (95% CI: 95·0, 96·8). The dengue model had a sensitivity of 86·1% (95% CI: 84·0, 87·8) and
an overall specificity of 88·8% (95% CI: 86·8, 90·6). The Zika model had a sensitivity of 68·2%

(95% CI: 64·1, 72·1) and an overall specificity of 95·4 (95% CI: 94·4, 96·3). **(B-D)** The five most

important clinical findings that helped correctly classify cases are shown for the chikungunya (B),

dengue (C), and Zika (D) models. Each dot represents the variable importance value of a given

clinical finding across 100 model iterations. Variables further to the right are more important for

classification purposes. If the presence of a clinical finding was important to the classification, it

is shown in dark blue; if its absence was important, it is shown in light blue. The top five most

important variables for each model, paired with information about whether their presence or

absence is relevant for classification, together determine how each given variable is helpful in

classifying cases. The lower and upper whiskers on the Tukey-style boxplots extend from the first

and third quartiles of the data to the smallest and largest values at most 1.5 times the interquartile

range, respectively. Data outside these whiskers are classically referred to as outliers.

Figure 1

755 **Figure 2**

757   **Figure 3**
758